For the Inventor, By the Inventor

Enter inventor name

André Schrattenholz

USPTO Granted Patents = 15 (Patent Applications = 14)

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 7)

Average Co-Inventor Count = 1.2

ph-index = 2

Forward Citations = 18(Granted Patents)

Company Filing History:

Years Active: 2009-2025

Loading Chart...

Loading Chart...

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12251423 - Method of effecting neuroprotection using soluble neuregulin isoforms (2025-03-18),

2. 10813978 - Method of effecting neuroprotection using soluble neuregulin isoforms (2020-10-27),

3. 10350269 - Method of effecting neuroprotection using soluble Neuregulin isoforms (2019-07-16),

4. 8546086 - Use of neuregulin-β as an indicator and/or target (2013-10-01),

5. 8466144 - Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents (2013-06-18),

6. 8409812 - Annexin A3 for cancer diagnosis (2013-04-02),

7. 8377648 - Autoimmune regulation of prostate cancer by annexin A3 (2013-02-19),

8. 8039464 - Muscarinic antagonists with PARP and SIR modulating activity as agents for inflammatory diseases (2011-10-18),

9. 8012697 - Monoclonal anti-annexin A3 antibodies for the detection of prostate carcinoma (2011-09-06),

10. 7998970 - Use of finasteride, dutasteride and related compounds for the prevention or treatment of neurologically-associated disorders (2011-08-16),

11. 7919582 - Neuregulin-β isoform (2011-04-05),

12. 7824923 - Neuregulin-β isoforms associated with neuronal processes (2010-11-02),

13. 7759068 - Use of substances for treating tumors (2010-07-20),

14. 7732148 - Annexin A3 for prostate cancer diagnosis (2010-06-08),

15. 7538197 - Use of neuregulin-β as an indicator and/or target (2009-05-26),

Title: André Schrattenholz: Innovator in Neuroprotection

Introduction

André Schrattenholz is a prominent inventor based in Mainz, Germany. He has made significant contributions to the field of neuroprotection, holding a total of 15 patents. His work primarily focuses on developing innovative solutions for cognition-related neurological disorders.

Latest Patents

One of his latest patents is a method of effecting neuroprotection using soluble neuregulin isoforms. This invention refers to soluble Neuregulin-1 isoforms representing posttranslational Neuregulin-1 modifications as medication in cognition-related neurological disorders, particularly schizophrenia, Alzheimer's, and Parkinson's diseases. This groundbreaking work aims to provide new therapeutic options for patients suffering from these debilitating conditions.

Career Highlights

Throughout his career, André Schrattenholz has worked with various companies, including Proteosys AG and Mind-NRG Sarl. His experience in these organizations has allowed him to refine his expertise and contribute to advancements in neuroprotective therapies.

Collaborations

André has collaborated with notable professionals in his field, including Michael Cahill and Vukic Soskic. These partnerships have further enhanced his research and development efforts.

Conclusion

André Schrattenholz is a dedicated inventor whose work in neuroprotection is paving the way for innovative treatments for neurological disorders. His contributions are vital in the ongoing quest to improve cognitive health and quality of life for many individuals.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…